PROVECTUS BIOPHARMACEUTICALS, INC.: 10-Q filed 2023-11-14
What PROVECTUS BIOPHARMACEUTICALS, INC. reported in its quarterly report filed 2023-11-14 (fiscal Q3 2023): 33 published measures, 99 facts as tagged in accession 0001493152-23-040856.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-11-14
- Fiscal period
- fiscal Q3 2023
- Accession
- 0001493152-23-040856 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PROVECTUS BIOPHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 1,690,093 | USD | |
| At 2022-12-31 | 2,037,246 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 9,209,297 | USD | |
| At 2022-12-31 | 8,265,756 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -7,519,204 | USD | |
| At 2023-06-30 | -7,296,881 | USD | |
| At 2023-03-31 | -7,001,763 | USD | |
| At 2022-12-31 | -6,228,510 | USD | |
| At 2022-09-30 | -6,858,570 | USD | |
| At 2022-06-30 | -6,147,087 | USD | |
| At 2022-03-31 | -5,068,918 | USD | |
| At 2021-12-31 | -4,187,280 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 367,250 | USD | |
| At 2022-09-30 | 67,030 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -775,839 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -2,438,355 | USD | 273 |
| 2023-04-01 to 2023-06-30 | -835,062 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -827,454 | USD | 90 |
| 2022-07-01 to 2022-09-30 | -713,267 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -2,822,030 | USD | 273 |
| 2022-04-01 to 2022-06-30 | -1,077,841 | USD | 91 |
| 2022-01-01 to 2022-03-31 | -1,030,922 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -2,010,767 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -2,286,682 | USD | 273 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 69,733 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 436,600 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 314,890 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 824,205 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 1,990,003 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 893,683 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -252,026,996 | USD | |
| At 2022-12-31 | -249,588,641 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 419,515,869 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 419,503,438 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 419,489,239 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 419,461,313 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 419,515,869 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 419,503,438 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 419,489,239 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 419,461,313 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 0 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -0.01 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | 0 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.01 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 0 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -0.01 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | 0 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.01 | USD/shares | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 14,250 | USD | |
| At 2022-12-31 | 20,941 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 2,850 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 3,025 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -714,148 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -2,296,564 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -666,189 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -2,744,227 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 1,592,334 | USD | |
| At 2022-12-31 | 1,899,182 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 9,171,583 | USD | |
| At 2022-12-31 | 8,192,380 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 1,785,322 | USD | |
| At 2022-12-31 | 2,094,258 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 783,881 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 2,733,164 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 981,079 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 3,568,432 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 350,792 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 1,333,399 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 580,390 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 2,068,154 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 419,522,119 | shares | |
| At 2022-12-31 | 419,497,119 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 244,101,958 | USD | |
| At 2022-12-31 | 242,954,193 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -36,207 | USD | |
| At 2022-12-31 | -35,679 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 83,509 | USD | |
| At 2022-12-31 | 117,123 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 84,860 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 108,764 | USD | |
| At 2022-12-31 | 102,073 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 181,180 | USD | |
| At 2022-12-31 | 467,081 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -775,839 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -2,438,796 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -714,508 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -2,824,315 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 433,089 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 1,399,765 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 400,689 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 1,500,278 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 6,691 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 8,857 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -61,691 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -141,791 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -47,078 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -77,803 | USD | 273 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 32,938 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 50,784 | USD | 273 |
Inspect the source
- Entity
- PROVECTUS BIOPHARMACEUTICALS, INC. / CIK 0000315545
- Captured
- 2026-09-19T14:56:22.911Z
- SEC response SHA-256
5c46f06a9f23badc21fb49ef63f53fb89ac39f7570babcbf8a64cddf67fb05d2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000315545.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))